Corbus Pharmaceuticals (NASDAQ:CRBP)‘s stock had its “buy” rating reiterated by equities researchers at Noble Financial in a research note issued on Tuesday.
Several other research firms also recently weighed in on CRBP. Raymond James Financial started coverage on Corbus Pharmaceuticals in a research note on Friday, January 19th. They set an “outperform” rating and a $24.00 price target for the company. BidaskClub downgraded Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Cantor Fitzgerald set a $32.00 price target on Corbus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday. Finally, ValuEngine upgraded Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $25.75.
Corbus Pharmaceuticals (NASDAQ CRBP) traded up $0.05 during mid-day trading on Tuesday, hitting $6.80. The stock had a trading volume of 919,941 shares, compared to its average volume of 1,000,000. The company has a market cap of $378.10, a P/E ratio of -10.63 and a beta of 152.04. Corbus Pharmaceuticals has a 12 month low of $5.30 and a 12 month high of $10.50.
Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04). Corbus Pharmaceuticals had a negative return on equity of 85.97% and a negative net margin of 1,040.41%. sell-side analysts predict that Corbus Pharmaceuticals will post -0.73 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. MetLife Investment Advisors LLC bought a new position in Corbus Pharmaceuticals in the 4th quarter worth about $164,000. Goldman Sachs Group Inc. bought a new position in Corbus Pharmaceuticals in the 4th quarter worth about $219,000. Deutsche Bank AG boosted its stake in Corbus Pharmaceuticals by 53.0% in the 4th quarter. Deutsche Bank AG now owns 114,842 shares of the biopharmaceutical company’s stock worth $814,000 after purchasing an additional 39,770 shares during the period. Geode Capital Management LLC boosted its stake in Corbus Pharmaceuticals by 10.2% in the 4th quarter. Geode Capital Management LLC now owns 409,365 shares of the biopharmaceutical company’s stock worth $2,905,000 after purchasing an additional 37,994 shares during the period. Finally, Sphera Funds Management LTD. bought a new position in Corbus Pharmaceuticals in the 4th quarter worth about $2,663,000. Institutional investors and hedge funds own 38.03% of the company’s stock.
WARNING: This report was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://ledgergazette.com/2018/03/14/corbus-pharmaceuticals-crbp-earns-buy-rating-from-noble-financial.html.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.